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A B S T R A C T
Sequencing very long stretches of the HIV-1 genome can advance studies on virus evolution and in vivo re-
combination but remains technically challenging. We developed an eﬃcient procedure to sequence near full-
length HIV-1 RNA using a two-amplicon approach. The whole genome was successfully ampliﬁed for 107 (88%)
of 121 plasma samples including samples from patients infected with HIV-1 subtype A1, B, C, D, F1, G, H,
CRF01_AE and CRF02_AG. For the 17 samples with a viral load below 1000 c/ml and the 104 samples with a
viral load above 1000 c/ml, the ampliﬁcation eﬃciency was respectively 53% and 94%. The sensitivity of the
method was further evaluated using limiting dilution of RNA extracted from a plasma pool containing an
equimolar mixture of three HIV-1 subtypes (B, C and CRF02_AG) and diluted before and after cDNA generation.
Both RNA and cDNA dilution showed comparable sensitivity and equal accuracy in reﬂecting the subtype dis-
tribution of the plasma pool. One single event of in vitro recombination was detected amongst the 41 sequences
obtained after cDNA dilution but no indications for in vitro recombination were found after RNA dilution. In
conclusion, a two-amplicon strategy and limiting dilution of viral RNA followed by reverse transcription, nested
PCR and Sanger sequencing, allows near full genome sequencing of individual HIV-1 RNA molecules. This
method will be a valuable tool in the study of virus evolution and recombination.
1. Introduction
The replicative cycle of HIV is characterized by high rates of nu-
cleotide misincorporations, insertions, deletions and recombinations
(Alizon and Montagnier, 1987; Cromer et al., 2016; Cuevas et al.,
2015). As a result, the homogeneous virus population typically present
early after infection soon evolves to a quasispecies of genetic variants
(Domingo et al., 1985). Characterization of this quasispecies can pro-
vide key information on the interplay between virus and host and on
virus evolution in general. Most studies on virus evolution are restricted
to relatively short fragments of the HIV-1 genome, often located in the
fast evolving envelope or gag region. Although next-generation sequen-
cing (NGS) technologies oﬀer new opportunities for full genome se-
quencing, an important constraint of NGS is the short read length of the
sequences and the resulting diﬃculty to link sequences over longer
distance. The more recently developed NGS technologies like PacBio RS
or Oxford Nanopore MinION may overcome these shortcomings but
they still suﬀer from high error rates (Dilernia et al., 2015).
Both the traditional Sanger sequencing and NGS require initial
ampliﬁcation of the genomic region of interest. Ampliﬁcation of the
HIV-1 RNA extracted from blood plasma as a single strand is extremely
challenging. As far as we know, only one successful attempt has been
described but this method was only evaluated on HIV-1 subtype C
(Rousseau et al., 2006). There were a few attempts to cover the genome
with two amplicons (Aralaguppe et al., 2016; Grossmann et al., 2015;
Nadai et al., 2008; Salazar-Gonzalez et al., 2009; Tovanabutra et al.,
2010) but in the majority of studies a four to six amplicon strategy is
used (Bimber et al., 2010; Brener et al., 2015; Di Giallonardo et al.,
2013; Fang et al., 1999; Gall et al., 2012; Ode et al., 2015; Walker et al.,
2012; Zagordi et al., 2010; Zanini et al., 2015). Reliable linking of the
sequences obtained from four or six independent amplicons is nearly
impossible, especially when analyzing highly divergent virus popula-
tions. For NGS there is the additional problem that the multiple se-
quences generated for each amplicon are of small read lengths. The
accurate assembly of these short sequences to reconstruct the individual
amplicons is also challenging (Posada-Cespedes et al., 2017). All these
problems impede research aimed at characterizing the HIV-1 quasis-
pecies composition, tracking immune evasion or studying in vivo
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recombination. As we were particularly interested in the study of re-
combination, we sought a way to amplify and sequence individual viral
variants over an as long as possible length. We developed a PCR pro-
tocol that covered the near full-length HIV genome with two amplicons.
We then assessed the sensitivity of the method and the possibility to
execute the ampliﬁcation on single viral RNA molecules using a limiting
dilution approach. With limiting dilution, in essence, the viral genetic
material is diluted to a point where no more than 30% of subsequently
performed PCR reactions are positive. In optimal conditions, the
mathematical probability that the amplicons subsequently generated
originate from a single genome, is higher than 80% (Rodrigo et al.,
1997). Limiting dilution was and still is an often applied method for
individual variant sequencing. Individual ampliﬁcation of single var-
iants is the only way to prevent PCR-induced recombination, a fre-
quently observed phenomenon when performing bulk sequencing
(Cronn et al., 2002; Gorzer et al., 2010; Judo et al., 1998; Liu et al.,
2014; Meyerhans et al., 1990; Yang et al., 1996). When using viral RNA
as input material for individual variant sequencing, it is standard
practice to ﬁrst reverse transcribe the RNA to cDNA followed by cDNA
end point dilution before ampliﬁcation. In vitro reverse transcription
however is a very ineﬃcient reaction, prone to recombination errors
and founder eﬀects. The ﬁnal result may be a library of amplicons that
does not adequately reﬂect the variant composition of the original
sample (Miranda and Steward, 2017; Salazar-Gonzalez et al., 2008;
Svarovskaia et al., 2003).
In the search for a more reliable method to study in vivo re-
combination of HIV-1 in patients co- or super-infected with diﬀerent
HIV-1 variants we developed an ampliﬁcation and sequencing strategy
that covers the near full-length HIV-1 genome with two amplicons. The
ampliﬁcation method was validated on a selection of plasma samples
with a broad range of viral loads and HIV-1 subtypes and on limiting
dilutions of both RNA and cDNA from a plasma pool with 3 diﬀerent
HIV-1 subtypes.
2. Materials and methods
2.1. Ethical approval
The study was approved by the Ethical Committee of Ghent
University Hospital (reference number 2014/0173). Patients provided
signed informed consent for the use of their leftover plasma for scien-
tiﬁc research. All samples were anonymized before processing.
2.2. Sample selection
Plasma samples were collected from 121 HIV-1 infected individuals.
For 87 individuals the infection stage at the time of sampling was de-
ﬁned, indicating collection during acute infection in 66 and during
chronic infection in 21. Patients were considered acutely infected if
they presented with detectable HIV p24 antigen and viral RNA in the
blood in the absence of HIV antibodies or if they were classiﬁed as
recently infected after testing in the Sedia HIV-1 LAg Avidity EIA test
(Sedia Biosciences, Portland, USA). This test has an estimated recency
window of 3 to 4 months (Verhofstede et al., 2017).
The selected samples covered a wide range of viral loads (mean:
58,884 copies(c)/ml) and included 17 samples with a viral load
of< 1000 c/ml; 13 samples with a viral load between 1000 and 10,000
c/ml and 91 samples with a viral load of> 10,000 c/ml. The subtype
variation reﬂected the subtype distribution in our country including
subtype B (n= 81), A1 (n=5), C (n=3), F1 (n=8) and CRF02_AG
(n=13) and some representatives of less frequently observed subtypes
A6 (n= 2), D (n= 2), G (n=2), H (n=1), CRF01_AE (n= 3) and
CRF06_cpx (n= 1).
2.3. Plasma pool
A plasma pool was prepared using plasma collected before ser-
oconversion from three patients infected with genetically diﬀerent
viruses (respectively HIV-1 subtype B, C and CRF02_AG). Collection
during the pre-seroconversion stage ensured low intra-patient genetic
variability of the virus. Using the HIV-1 viral load as a reference, the 3
samples were diluted in HIV negative plasma to a calculated con-
centration of 50,000 RNA c/ml each. Re-analyses of the viral load of the
diluted samples showed a result of 44,000 c/ml, 55,000 c/ml and
63,500 c/ml respectively, for the subtype B, C and CRF02_AG sample.
Equal volumes of each of these dilutions were pooled to create a pool
with nearly equimolar representation of the three subtypes.
2.4. RNA extraction
Viral RNA was extracted using the QIAamp Viral RNA Mini kit
(Qiagen, Hilden, Germany) following the manufacturer’s instructions.
For each extraction, 140 μl of plasma was used as input material.
Puriﬁed RNA was eluted in 60 μl and stored at −20 °C until use.
For the plasma pool, 20 individual extractions were performed in
order to obtain suﬃcient amounts of RNA for all experiments and to
minimize the impact of extraction-induced diﬀerences in variant com-
position. The resulting extracts were pooled, aliquoted and stored at
−20 °C until use.
2.5. Reverse transcription
Bulk reverse transcription (RT) was done with SuperScript™ III
(Thermo Fisher Scientiﬁc, Massachusets, USA) and the reverse primers
F3_rev1 and F6_rev1 (Table 1) to reverse transcribe respectively the 5′
and the 3′ half of the HIV-1 genome. For each reaction, 2.5mM reverse
primer (1 μl) and 10mM dNTP’s (1 μl) was added to 11 μl RNA. After
heating the mixture to 65 °C for 5min and cooling down for 1min, a
reaction mix of 5X RT buﬀer (4 μl), 100mM DTT (1 μl), 40 U RNAsin
(1 μl) and 200 U Superscript RT (1 μl) was added and the reaction
mixture was heated to 50 °C for 60min and 70 °C for 15min followed
by a cool down to 4 °C. The resulting cDNA was then ampliﬁed using
the Platinum™ Taq DNA Polymerase High Fidelity kit (Thermo Fisher
Scientiﬁc, Massachusetts, USA). The primer sets used for ampliﬁcation
consisted of the same primers as used for cDNA generation supple-
mented with the sense primer F1_fw1 for the 5′ fragment and F4_fw1 for
the 3′ fragment. For each reaction, 5 μl of the generated cDNA was
added to 45 μl of a reaction mix containing molecular biology grade
water (34.8 μl), 10X High Fidelity buﬀer (5 μl), 50mM MgSO4 (2 μl),
10mM dNTPs (1 μl), 1 U Platinum Taq (0.2 μl) and 10 pmol/μl primer
(1 μl of each). Cycling conditions were 15 s at 94 °C, 30 s at 50 °C and
5min at 68 °C for 30 repetitions with a ﬁnal extension of 5min at 68 °C
and a cool down to 4 °C.
For the reverse transcription of RNA after limiting dilution, the re-
verse transcription step and ﬁrst round PCR were combined in a single
reaction using the Superscript III One-Step RT-PCR Platinum Taq HiFi
kit™ (Thermo Fisher, Massachusets, USA). This kit contains an enzyme
mixture of SuperScript™ III and Platinum™ Taq DNA Polymerase.
Fourteen μl of RNA was added to a reaction mix containing molecular
biology grade water (8 μl), 2X reaction mix (25 μl), enzyme mix (1 μl)
and 10 pmol/μl (1 μl) of either the primers deﬁning the 5′ part of the
genome (F1_fw1 and F3_rev1) or the primers deﬁning the 3′ part of the
genome (F4_fw1 and F6_rev1). The reaction conditions were 30min at
50 °C followed by 2min of denaturation at 94 °C for the reverse tran-
scription followed by 30 ampliﬁcation cycles (15 s at 94 °C, 30 s at 50 °C
and 5min at 68 °C). The reaction was ended with a ﬁnal extension of
5min at 68 °C followed by a cool down to 4 °C.
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2.6. Nested PCR
Two and a half μl of the amplicons generated during ﬁrst-round
ampliﬁcation was transferred to 47.5 μl of a reaction mix containing 1 U
(0.2 μl) Platinum™ Taq DNA Polymerase (Thermo Fisher Scientiﬁc,
Massachusetts, USA), 10mM dNTPs (1 μl), 10X High Fidelity buﬀer
(5 μl), 50mM MgSO4 (2 μl), molecular biology grade water (37.3 μl)
and 10 pmol/μl (1 μl) of the nested primers F1_fw2 and F3_rev2 for the
5′ fragment or F4_fw2 and F6_rev2 for the 3′ fragment. The reaction
mixes (total volume of 50 μl for each fragment) were then subjected to
30 cycles of 30 s at 94 °C, 15 s at 55 °C and 4min at 60 °C. The presence
of an amplicon with a respective length of 4511 nucleotides (nt) for the
5′ fragment and 4627 nt for the 3′ fragment was visualized on a 2%
agarose gel (Roche Applied Science, Mannheim, Germany), using the
GeneRuler 1 kb Plus DNA ladder as DNA size reference (Thermo Fisher
Scientiﬁc, Massachusetts, USA).
2.7. Sanger sequencing
Positive PCR products were puriﬁed with Agencourt AMPure beads
(Beckman Coulter, California, USA). For BigDye™ Terminator v3.1
Cycle Sequencing (Life Technologies, Carlsbad CA, USA), 2 μl of the
puriﬁed amplicon was added to a mixture of 5X Sequencing Buﬀer
(1.75 μl), 1X BigDye® Terminator v3.1 Ready Reaction Mix (0.5 μl),
2 pmol/μl primer (2.5 μl) and molecular biology grade water (3.25 μl).
For each amplicon at least 18 sequencing reactions were run with the
sequencing primers listed in Table 1. Reactions were subjected to 30
cycles of 15 s at 94 °C, 30 s at 50 °C and 5 s at 68 °C, followed by a cool
down to 4 °C and then puriﬁed using Agencourt CleanSEQ™ beads
(Beckman Coulter, California, USA) before analysis on the 3500 or 3500
XL Genetic Analyzer (Applied Biosystems, Thermo Fisher Scientiﬁc,
Massachusetts, USA). Proofreading of the chromatograms was done
with Smartgene IDNS (Smartgene, Zug, Switzerland). Amplicons with
mixed nucleotides were omitted from subsequent analyses.
Because we encountered problems to sequence the highly variable
envelope region of some HIV-1 variants, additional primers were de-
signed to improve the sequencing of this region. These primers are
listed in Table 1 as ‘alternative’ primers. They were validated on a se-
lection of 3′ amplicons from 6 patients, including the three patients that
constituted the plasma pool. Due to shortage of material however the
Table 1
Primers used for ampliﬁcation and sequencing of the near full-length HIV-1 genome. RT= reverse transcription; Seq= sequencing; *Position based on HXB2
numbering; °Alternative primers.
Primer Direction Start position* Stop position* Sequence (5’→’3) Function
F1_fw1 Forward 524 547 CTCAATAAAGCTTGCCTTGAGTGC First PCR
F3_rev1 Reverse 5185 5213 GGGATGTGTACTTCTGAACTTAYTYTTGG RT+First PCR
F4_fw1 Forward 4899 4922 CGGGTTTATTWCAGRGAGAGCAGA First PCR
F6_rev1 Reverse 9592 9614 ATTGAGGCTTAAGCAGTGGGTTC RT+First PCR
F1_fw2 Forward 551 571 AAGTAGTGTGTGCCCGTCTGT Nested PCR+ Seq
F3_rev2 Reverse 5040 5061 CACCTGCCATCTGTTTTCCATA Nested PCR+ Seq
F4_fw2 Forward 4956 4974 TGGAAAGGTGAAGGGGCAG Nested PCR+ Seq
F6_rev2 Reverse 9567 9582 CCAGAGAGCTCCCAGG Nested PCR+ Seq
G40 Forward 1075 1093 GACACCAAGGAAGCTTTAG Seq
GAG8 Reverse 1473 1500 TGCTATGTCACTTCCCCTTTGTTCTCTC Seq
1231F Forward 1231 1255 TCACCTAGAACTTTRAATGCATGGG Seq
1817F Forward 1817 1834 TAGAAGAAATGATGACAG Seq
F2_fw2 Forward 2022 2039 GGGCTGTTGGARATGTGG Seq
PR3 Forward 2148 2166 AGAGCCAACAGCCCCACCA Seq
RT2955 Reverse 2955 2977 CTAATYCCTGGYGTYTCATTRTT Seq
F1_rev2 Reverse 2252 2272 TGCCAAAGAGTGATYTGAGGG Seq
R5 Reverse 3492 3511 GGGTCATAATACACTCCATG Seq
IN_MW1 Forward 2997 3019 CCACARGGATGGAAAGGATCACC Seq
F3_fw2 Forward 3681 3703 GAAAGCATAGTRATATGGGGAAA Seq
F2_rev2 Reverse 3776 3799 ACAAACTCCCAYTCAGGAATCCA Seq
4350R Reverse 4326 4350 CACAGCTAGCTACTATTTCTTTTGC Seq
IN99 Reverse 4482 4504 TCTGCTGGRATRACYTCTGCYTC Seq
IN22 Forward 4074 4095 CAACCAGAYAARAGTGARTCAG Seq
IN88 Forward 4608 4627 AAGGCIGCMTGYTGGTGGGC Seq
ENVoutF1 Forward 5550 5574 AGARGAYAGATGGAACAAGCCCCAG Seq
5861F Forward 5861 5884 TGGAAGCATCCRGGAAGTCAGCCT Seq
ACC8R Reverse 5968 5989 TCTCCGCTTCTTCCTGCCATAG Seq
F4_rev2 Reverse 6429 6450 GTACACAGGCATGTGTRGCCCA Seq
F5_rev2 Reverse 7992 8012 CCAAATYCCYAGGAGCTGTTG Seq
7382 Reverse 7357 7382 ATTACARTAGAAAAATTCYCCTCYAC Seq
7336 Reverse 7318 7336 ATTTCTGGRTCYCCKCCTG Seq
6990 Forward 6990 7012 TCAACHCAAYTRCTGTTAAATGG Seq
6951 Forward 6951 6973 AGYRCAGTACAATGYACACATGG Seq
7373R Reverse 7350 7373 GAAAAATTCTCCTCYACAATTAAA Seq
7761F Forward 7761 7787 GTGGGAATAGGAGCTGTGTTCCTTGGG Seq
KVL072 Forward 8330 8355 AATAGAGTTAGGMAGGGATACTCACC Seq
8445R Reverse 8424 8445 CTCTCTCTCCACCTTCTTCTTC Seq
ENVM Reverse 9058 9086 TAGCCCTTCCAGTCCCCCCTTTTCTTTTA Seq
F_ENVM Forward 9058 9086 TAAAAGAAAAGGGGGGACTGGAAGGGCTA Seq
nefyn05 Reverse 9157 9181 GTGTGTAGTTCTGCCAATCAGGGAA Seq
°ENV6889R Reverse 6865 6889 CCAGCYGGRGCACAATAATGTATRG Seq
°ENV6865F Forward 6865 6889 CYATACATTATTGTGCYCCRGCTGG Seq
°ENV7538R Reverse 7521 7538 RGGAGGRGCATAYATTGC Seq
°ENV7521F Forward 7521 7538 GCAATRTATGCYCCTCCY Seq
°ENV7957R Reverse 7936 7957 GCCTGGAGCTGYTTRATGCCCC Seq
°ENV7936F Forward 7936 7957 GGGGCATYAARCAGCTCCAGGC Seq
°ENV6328F Forward 6328 6348 GGGTYACAGTHTATTATGGRG Seq
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primers could not be tested on the diﬀerent individual amplicons gen-
erated from the plasma pool.
2.8. Viral load
Viral load analysis was performed using the Cobas ® HIV-1 test
(Roche Diagnostics, Basel, Switzerland).
2.9. Subtyping and phylogenetic analysis
Subtyping was done based on the polymerase sequences obtained
through standard of care baseline resistance testing using the HIV-1
subtyping tool COMET (COntext-based Modeling for Expeditious
Typing)(Struck et al., 2014). JpHMM (jumping proﬁle Hidden Markov
Model) (Schultz et al., 2012) was used to visualize potential re-
combination events. Identiﬁed recombinants were conﬁrmed using the
bootscanning method in Simplot (Lole et al., 1999).
Phylogenetic trees were constructed with PhyML 3.0 using the AIC
(Akaike Information Criterion) selection, the NNI (Nearest Neighbour
Interchange) tree-rearrangement and the aLRT SH-like (approximate
Likelihood Ratio test and Shimodaira–Hasegawa) method for branch
support (Guindon et al., 2010). Trees were visualized with iTol (Letunic
and Bork, 2016).
The Genbank accession numbers of the sequences generated during
this study are: MN485971-MN486047.
3. Results
3.1. Ampliﬁcation of near full-length HIV-1 RNA
Primers for reverse transcription, ﬁrst round and nested PCR were
selected from the work of Zanini et al. (2015). For their amplicon li-
brary preparation, these authors generated six overlapping amplicons,
together covering nt 571 to 9567 of the HIV genome. In an attempt to
reduce the number of independent amplicons, we ﬁrst tried to combine
the outermost 5′ and 3′ primers but all attempts to generate a single
full-length amplicon failed. We then combined the outermost 5′ and 3′
primers (F1_fw1 and F6_rev1) with primers located in the center of the
genome (F3_rev1 and F4_fw1) for the reverse transcription and ﬁrst
round PCR and the primers F1_fw2 and F3_rev2 and F4_fw2 and F6_rev2
for the nested ampliﬁcation. This allowed to generate two amplicons
with a short overlap, covering respectively nt 551 to 5061 (5′ fragment)
and nt 4899 to 9582 (3′ fragment) of the HIV genome. The success rate
and sensitivity of the reverse transcription PCR for 121 plasma samples
was 90% for the 5′ fragment and 95% for the 3′ fragment. For 88% both
amplicons could be generated. For the 17 samples with a viral load of
less than 1000 c/ml that were included, the success rate was 65% for
the 5′ fragment and 76% for the 3′ fragment. For 9 samples (53%) both
fragments were generated. The viral loads of these 9 samples were 144
c/ml, 288 c/ml, 324 c/ml, 330 c/ml, 389 c/ml, 449 c/ml, 492 c/ml,
575 c/ml and 610 c/ml.
3.2. RNA limiting dilution
To further assess the sensitivity of the two-amplicon reverse tran-
scription PCR, serial dilutions of viral RNA extracted from a plasma
pool with subtype B, C, and CRF02_AG viruses were tested. RNA was
diluted 1/1, 1/5, 1/10, 1/20, 1/30, 1/40, 1/50, 1/60 in molecular
biology grade water (VWR, Pennsylvania, USA) and each dilution was
subjected to reverse transcription PCR. Successful ampliﬁcation was
seen up to a dilution of 1/40 and 1/50 respectively for the 5′ and 3′
amplicon. These dilutions were selected as probable endpoints and 10
replicates of both were retested. With 3/10 positive reactions for the 1/
50 dilution, for both fragments, this dilution, that corresponded to a
calculated input equivalent of 32.8 RNA copies per reaction, complied
with the conditions for being considered as the endpoint. To increase
the number of individual amplicons for subsequent sequencing, 90 re-
plicates of the 1/50 dilution were additionally subjected to RT-PCR.
Finally, respectively 28 and 25 individual 5′ amplicons and 3′ ampli-
cons were available for sequencing. The subtype distribution of these
amplicons is shown in Table 2. No intersubtype recombinants were
detected.
3.3. cDNA limiting dilution
cDNA resulting from bulk reverse transcription of plasma pool RNA,
was diluted 1/1, 1/5, 1/10, 1/20 and 1/40 in molecular biology grade
water (VWR, Pennsylvania, USA) and subjected to two rounds of PCR to
generate the 5′ and 3′ amplicons. Positive reactions were obtained up to
the 1/10 dilution for the 5′ fragment and up to the 1/5 dilution for the
3′ fragment. For both dilutions the reactions were repeated in 10-fold.
This revealed a 30% success for the 1/5 dilution for both fragments.
This dilution, corresponding to a calculated input equivalent of 64.3
copies viral RNA per reaction, was considered as the endpoint and 90
additional replicates were tested to ﬁnally result in 21 and 20 in-
dividual amplicons of respectively the 5′ and the 3′ fragment. The
subtype distribution of the resulting sequences is shown in Table 2. One
of the 3′ amplicons (cDNA_F2_8) showed clear indications of in vitro
recombination, with a small stretch of subtype C in a CRF02_AG
background. The recombination is demonstrated by both the high-
lighter plot (Fig. 1B), the phylogenetic tree (Fig. 2B) and Simplot (S1).
3.4. Sequencing reactions
Amplicons were sequenced bidirectional using 36 sequencing pri-
mers including the primers used for the nested PCR. For the 3′ ampli-
cons, some problems were encountered for part of the variable envelope
gene with failing sequencing reactions for the region between nt 6391
and 6723 for subtype C virus and between nt 7965 and 8331 for
CRF02_AG (Fig. 1B). An overview of all sequences presented as high-
lighter plots with the HXB2 sequence as a reference is shown in Fig. 1A
for the 5′ amplicons, and in Fig. 1B for the 3′ amplicons. The phylo-
genetic trees are illustrated respectively in Fig. 2A and B.
Table 2
Subtype distribution of the amplicons generated from a plasma pool containing an equimolar mix of HIV-1 subtype B, C and CRF02_AG after limiting dilution of
respectively RNA and cDNA.
Limiting dilution
RNA cDNA
5’ amplicon 3’ amplicon 5’ amplicon 3’ amplicon Total
Number of clones 28 25 21 20 94
Subtype CRF02_AG 15 (53.6%) 8 (32.0%) 9 (42.9%) 3 (15.0%) 35 (37.2%)
Subtype C 10 (35.7%) 7 (28.0%) 8 (38.1%) 6 (30.0%) 31 (33.0%)
Subtype B 3 (10.7%) 10 (40.0%) 4 (19.0%) 10 (50.0%) 27 (28.7%)
Recombinant form – – – 1 (5.0%) 1 (1.1%)
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4. Discussion
The aim of this study was to develop a method for ampliﬁcation and
sequencing of nearly complete individual HIV-1 viral RNA molecules,
using a minimum number of ampliﬁed fragments. A two-amplicon ap-
proach, generating amplicons with a length of 4511 nt and 4627 nt,
respectively covering the 5′ and 3′ half of the viral genome, was de-
signed and validated. Ampliﬁcation primers were selected from the
study of Zanini et al. (2015). Successful ampliﬁcation of both fragments
was obtained for viral RNA extracted from the plasma of 107 (88%) of
121 HIV-1 infected individuals, including 9 (53%) of 17 samples with a
viral load of< 1000 c/ml. Aralaguppe et al. (2016) and Grossmann
et al. (2015) also successfully used a two-amplicon approach to se-
quence the whole HIV-1 genome but the sensitivity of their protocol
was limited to 3000 c/ml. In other studies, the whole viral genome was
reconstructed with four to six overlapping amplicons with read lengths
of less than 4000 nt (Alampalli et al., 2017; Berg et al., 2016; Brener
et al., 2015; Di Giallonardo et al., 2013; Dukhovlinova et al., 2018; Gall
et al., 2012; Ode et al., 2015; Walker et al., 2012; Zanini et al., 2015).
The problem of this more extensive fragmentation is that genomic
linkage is limited to the individual pieces. This hampers insight on the
overall evolution of the genome and is a major drawback in studies on
in vivo recombination.
The primers used were originally designed to cover a broad range of
viral genetic variability (Zanini et al., 2015). The high speciﬁcity for
diﬀerent subtypes was conﬁrmed by the successful ampliﬁcation of
subtype A1, A6, B, C, D, F1, G, H, CRF01_AE and CRF02_AG.
Because of the high intra-patient variability of HIV-1, studying the
genetic evolution not only requires the generation of long amplicons
but also the possibility to sequence individual viruses. NGS seems to be
the most appropriate method to do so but up to now it remains ex-
tremely diﬃcult to reconstruct long sequences from the short read
length sequences generated by NGS. We therefore explored the poten-
tial of limiting dilution sequencing using either RNA or cDNA as
starting material and were surprised to see that despite the long am-
pliﬁcation length, both are feasible and equally sensitive. In vitro re-
verse transcription is generally considered as very ineﬃcient. This, and
the expected lability of RNA molecules, most probably account for the
fact that in studies where sequencing of individual viruses is performed,
viral RNA is ﬁrst bulk transcribed to cDNA before proceeding to in-
dividual strand ampliﬁcation. This strategy holds a risk for errors and in
vitro recombination (Salazar-Gonzalez et al., 2008; Seifert et al., 2016),
a risk that increases with transcript length. Fang et al. (1999) showed a
2.5-fold higher in vitro recombination rate for RT-PCR compared to PCR
alone (6.49% vs. 2.65%) when amplifying a fragment of 4.5 kb. Di
Giallonardo et al. (2013) reported an overall in vitro recombination
frequency after RT-PCR of 53.6% when using a mixture of HIV-1 RNA,
though a contribution of the RT step on the in vitro recombination was
not demonstrated, probably because of the very short amplicon length
(290 bp). In other reports, the estimated in vitro recombination fre-
quencies during PCR ranged from<1% to 7% (Bradley and Hillis,
1997; Judo et al., 1998; Meyerhans et al., 1990; Mild et al., 2011; Yang
et al., 1996) but frequencies as high as 30% have been reported (Cronn
et al., 2002; Yu et al., 2006).
We constructed a plasma pool with equal concentrations of subtype
B, C and CRF02_AG virus and explored the possibility to dilute the
Fig. 1. Highlighter plot of sequences generated after limiting dilution of HIV-1 RNA and cDNA from a plasma pool with 3 HIV-1 variants.
(A) Highlighter plot of the 5′ amplicon sequences. (B) Highlighter plot of the 3′ amplicon sequences. Sequences are aligned to the HXB2 reference sequence (master
sequence (m)). Mutations are color coded. Zones of bad sequence quality are displayed in gray. The corresponding subtype is indicated on the left. The sequences are
identiﬁed with the target of limiting dilution (RNA or cDNA), the fragment (F1: 5′ amplicon; F2: 3′ amplicon) and a serial number.
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Fig. 2. Phylogenetic trees of sequences gener-
ated after limiting dilution of HIV-1 RNA or
cDNA from a plasma pool with 3 HIV-1 variants.
Phylogenetic tree of the 5′ amplicon sequences
(A) and of the 3′ amplicon sequences (B). The
tree is rooted on a A1 reference sequence
(Ref_A1). A reference sequence was also added
for each of the 3 subtypes (Ref_B, Ref_C,
Ref_02AG). Branches are colored according to
the subtype (02_AG: red, B: blue, C: green).
Sequences are identiﬁed with the target of lim-
iting dilution (RNA or cDNA), the fragment (F1:
5′ amplicon; F2: 3′ amplicon) and a serial
number. aLTR SH-like node support values>
0.98 are indicated with black squares.
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extracted viral RNA before cDNA generation in an attempt to prevent in
vitro recombination. The results evidenced the feasibility of this
strategy. In vitro recombination could be documented in one amplicon
generated after cDNA dilution but no evidence of in vitro recombination
was found in the amplicons obtained after RNA limiting dilution. Gall
et al. (2012) used endpoint dilution of cDNA from a mixture of HIV-1
subtype B and C to assess occurrence of in vitro recombination. They
detected 1 recombinant among 64 individual sequences (1.56%). It is
clear to say that both in the study of Gall et al. and in our study, in vitro
recombination remained rare but occurred and thus deﬁnitely con-
stitutes a potential bias in studies on viral diversity and evolution (Gall
et al., 2012).
The rationale behind limiting dilution as a way to perform clonal
ampliﬁcation is that there is a calculated chance of 80% that a positive
reaction derives from a single molecule when a maximum of one-third
of replicate reactions is positive (Rodrigo et al., 1997). This however
assumes that the ampliﬁcation reaction has a one copy sensitivity. It is
unlikely that this is the case in our experiments, considering the very
long ampliﬁcation length. Based on the initially measured viral load of
the plasma pool and assuming that no RNA is lost during the extraction
process, each replicate endpoint dilution reaction contained a calcu-
lated equivalent of 32.8 RNA copies. More than one target RNA mole-
cule may thus be present in a single reaction tube after limiting dilu-
tions and in vitro recombination between these molecules cannot be
fully excluded, though is expected to be rare. Lower target RNA con-
centrations have been associated with a decreased artiﬁcial chimera
formation in RT-PCR (Waugh et al., 2015). We used Superscript III, a
reverse transcriptase shown to be very sensitive and reliable for low
copy number RNA samples (Okello et al., 2010). In the latter study,
Superscript III consistently allowed ampliﬁcation of 10 copies of an
armored RNA preparation but the length of the ampliﬁed fragment
(142 nt) was considerably smaller than the 4500 nt in our experiments.
Using Superscript III, Palmer et al. (2003) succeeded in reverse tran-
scribing and amplifying single copies of RNA transcripts from a plasmid
containing a HIV-1 gag fragment of 554 bp.
We have no idea about the amount of RNA that is lost or de-
generated during the extraction procedure. We used a manual extrac-
tion with the QIAamp Viral RNA Mini kit (Qiagen). In a recently pub-
lished comparison of HIV-1 RNA extraction protocols for subsequent
high-throughput sequencing, this kit produced the highest number of
successfully ampliﬁed long amplicons (Cornelissen et al., 2017).
An important additional prerequisite for procedures that aim at
characterizing complex virus populations is that the ﬁnal result ade-
quately reﬂects the variant composition in the initial sample. Whether
using limiting dilution of RNA or limiting dilution of cDNA, all three
subtypes present in the sample pool were recovered. Some diﬀerences
in the overall distribution of the subtypes were noticed but these were
most probably due to stochastic variation considering the low number
of individual variants analyzed. There were no indications for a sys-
tematic over or underreporting of a particular subtype. If the results for
all amplicons were added, the distribution was 35 (37.2%) for the
CRF02_AG strain, 31 (33.0%) for subtype C and 27 (28.7%) for subtype
B. Gall et al. (2012) sequenced 64 ampliﬁed products of a 1:1 plasma
mixture (subtype B and C) using endpoint dilution and observed a
distribution of 71.9% and 26.6% in relation to the initial viral loads of
respectively 360,000 c/ml and 120,000 c/ml. It is clear that the accu-
racy with which the initial variability is grabbed will increase with
increasing numbers of individual variants analyzed. In general, how-
ever typically 20–40 single genomes are analyzed in limiting dilution
PCR experiments (Palmer et al., 2003). Possible founder eﬀects can be
limited by pooling a number of independent RNA isolations before
proceeding to the RNA dilution as we did for the plasma pool.
For this study, we mainly concentrated on the generation of am-
plicons and less on the optimization of the sequencing reaction. For the
sequencing reaction, 18 primers were used per amplicon. In ideal cir-
cumstances, this allowed to cover both amplicons bi-directionally.
Problems were however encountered for the envelope region for some
samples. To overcome gaps in the envelope sequence, alternative se-
quencing primers were designed.
An important limitation of the protocol developed is that the
overlap between the two amplicons is short (105 nt) and does not allow
the reliable linkage of the sequence obtained for both fragments to a
single RNA molecule. Also, in order to achieve individual variant am-
pliﬁcation we used a nested ampliﬁcation protocol which may increase
the risk of contamination. Careful examination of phylogenetic trees
constructed with all obtained sequences could not show any evidence of
contamination in our experiments.
In summary, this study presents a method for individual variant
sequencing of the near full-length HIV-1 genome using two amplicons.
The method is able to generate individual sequences from plasma
samples with a viral load of less than 1000 c/ml. The method is unique
in that it allows to link genomic regions over a distance covering half of
the viral genome. The possibility to dilute the viral RNA to the extreme
before reverse transcription was successfully explored as a way to se-
quence individual variants while limiting the chance for in vitro re-
combination. The protocol was set up using Sanger sequencing but
adaptation of the limiting dilution PCR for preparation of NGS libraries
must be feasible.
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